Author + information
- Venu Gopal Jonnalagadda, M.S. Pharm∗ (, )
- Kanchan Choudhary, M. Pharm and
- Vijay Kranti Matety, M.S. Pharm
- ↵∗Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Bhangagarh, Guwahati, Assam-781006, India
We read the article “Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial” by McMurray et al. (1) and found it interesting to learn about the effectiveness of vildagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with heart failure and reduced left ventricular ejection fraction (LVEF) compared with placebo.
In the study results (i.e., in Table 1 of the article ), the authors reported that, in the vildagliptin group (n = 128) and the placebo group (n = 126), 71.1% and 70.7% of patients, respectively, were taking loop diuretics at baseline. However, in other measurements of heart failure status, it was reported as 64.8% and 65.9% of patients in the vildagliptin and the placebo groups.
Moreover, in follow-up and adherence (1), it was stated that the number of protocol violations in the vildagliptin group was 3 and in the placebo group it was 2 patients, respectively. However, Figure 2 from the article by McMurray et al. (1) indicates those 3 patients in the vildagliptin group and 2 patients in the placebo group were protocol deviations.
We would be grateful if the authors (1) would kindly consider clarifying these aforementioned items in their article to avoid discrepancy and highlight a clear idea of the effect of vildagliptin, a dipeptidyl peptidase-4 inhibitor for patients with heart failure and reduced left ventricular ejection fraction in type 2 diabetes mellitus.
Please note: The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- 2018 American College of Cardiology Foundation